DOCSLIB.ORG
Explore
Sign Up
Log In
Upload
Search
Home
» Tags
» Eliglustat
Eliglustat
Drug Consumption in 2017 - 2020
NTSAD Web Page on Miglustat Fran Platt Substrate Reduction Therapy
2021 Formulary List of Covered Prescription Drugs
Specialty Drugs Requiring Precertification
State and Specialty Pharmacy Drug Reimbursement Rates
DTF Prior Authorization Drug List
Drug Consumption at Wholesale Prices in 2017 - 2020
Gaucher Disease Agents
CERDELGA Safely and Effectively
Lists of Medicinal Products for Rare Diseases in Europe*
Formulary Drug List
Eliglustat (CERDELGA™)
WHO Drug Information Vol
The Importance of Patient-Specific Factors for Hepatic Drug Response
Appendix B - Product Name Sorted by Applicant
Perioperative Medication Management - Adult/Pediatric - Inpatient/Ambulatory Clinical Practice Guideline
CERDELGA 84 Mg, Gélule Boîte De 56 (CIP : 34009 300 087 8 2)
Reseptregisteret 2014–2018 the Norwegian Prescription Database 2014–2018
Top View
205494Orig1s000
Investigating Endothelial Dysfunction in a CRISPR/Cas9 Model of Fabry Disease
March 6 Transcript
CERDELGA (Eliglustat) RATIONALE for INCLUSION in PA PROGRAM
Essential List of Medicinal Products for Rare Diseases: Recommendations from the Irdirc Rare Disease Treatment Access Working Group William A
Cerdelga, INN-Eliglustat
Appendix F9. University of Maryland Health Partners (UMHP) Prescription Drugs Subject to Nqtls, by Delivery System
Self-Administered Specialty Drug List
Eliglustat (Cerdelga®) EOCCO POLICY Policy Type: PA/SP Pharmacy Coverage Policy: EOCCO135
Cerdelga Eliglustat Molina Clinical Policy
TITLE: Eliglustat Tartrate, Miglustat, Imiglucerase, Velaglucerase Or A
Specialty Formulary
57 Orphan Drugs Approved by the EC Between 2012 and 2016 Were Found, of Which 40 (70.2%) Had Been Authorised in Spain
Rare Disease Treatment Resource Guide
State and Specialty Pharmacy Drug Reimbursement Rates
ATC-Index Mit DDD-Angaben Für Deutschland Im Jahre 2019
ABSTRACT BOOK 23Rd EAHP Congress 2018 March 21St–23Rd Sweden Gothenburg
State and Specialty Pharmacy Drug Reimbursement Rates
Appendix a - Product Name Index
Drugs Requiring Transmission of a Diagnosis Code
Outcomes of Paediatric Drug Development from a Labeling
Orange Book Cumulative Supplement 7 July 2021
Journal of Population Therapeutics & Clinical Pharmacology
Appendix A: Perioperative Medication Management
Profound Endothelial Dysfunction and Inflammation in Fabry Disease: Responses to Exercise Training
AHFS Pharmacologic-Therapeutic Classification System
Eliglustat (Genz 112638) As Inhibitor Of
FEP 5 Tier Managed Rx Drug Formulary (807) Basic Option
Non-Preferred Drug List (NPDL)
Prior Authorization — Premium
Paragraph IV Patent Certifications (PPIV)
Gaucher Disease Agents
Cerdelga (Eliglustat)
Current Strategies for the Treatment of Inborn Errors of Metabolism
Cerdelga™ (Eliglustat Tartrate) Capsules
Routine Practice Data for the Benefit Assessment of Drugs 10 January 2020
Antiviral Activity of Glucosylceramide Synthase Inhibitors Against SARS-Cov-2 and Other RNA Virus Infections
Utah Medicaid Dur Report December 2017 Overview Of
Specialty Pharmacy Drug List Specialty Medications List
Drug Formulary Update, October 2016 Commercial and State Programs
Eliglustat (Cerdelga) Reference Number: USS.SPMN.137 Effective Date: 10/16 Last Review Date: 09/16 Revision Log
CERDELGATM Safely and Effectively
UMP (Wsrxs) Preferred Drug List (PDL) 2021
The Glycosphingolipid Inhibitor Eliglustat Inhibits Autophagy in Osteoclasts To
November 2020
Quarterly Pharmacy Changes Effective Jan. 1, 2021 – Part 2
Dynamic Therapeutic Formulary Prior Authorization Drug List
Annual Report 2015 Annexes